Ataxia-pancytopenia (ATXPC; MIM 159550) syndrome is an autosomal dominant disease with early-onset gait and balance impairment, nystagmus, mild pyramidal signs, and marked cerebellar atrophy. Hematological abnormalities in ATXPC include pancytopenia, which may remain subclinical but can cause severe infections or hemorrhages. Through different genetic mechanisms in blood cells, the hematopoietic phenotype may be reverted. Elimination of the germ-line *SAMD9L* mutation by loss of chromosome 7(q) can result in myeloid malignancies.^[@R1]^ ATXPC has so far been described in 5 families,^[@R1][@R2][@R5]^ including the Swedish family (F1) and Finnish family (F2) reported here. Recently, missense mutations in sterile alpha motif domain--containing protein 9-like (*SAMD9L*) have been identified as the cause of ATXPC in 4 of these families.^[@R1],[@R5]^ Following the genetic discovery, we studied the neurologic phenotype in F1 and F2.

METHODS {#s1}
=======

Affected and unaffected family members of both families were examined by a neurologist. A structured interview and examination were performed including all clinical features previously described in ATXPC families,^[@R2][@R3][@R5]^ and the Scale for the assessment and rating of ataxia.^[@R6]^ Neuroradiologic images were compiled. Eye movement examination was filmed and reviewed by a neuro-otologist. Medical records were obtained whenever possible. Results of previous blood cell counts were reviewed, and new blood samples were taken. DNA was extracted using standard methods from the peripheral blood or buccal swabs.^[@R1]^ Some of the genetic analyses and clinical (hematologic) information have previously been published.^[@R1]^ For this study, F1 was expanded; newly included family members were tested with a custom droplet digital PCR TaqMan genotyping assay for the *SAMD9L* c.2956C\>T mutation (primers available on request). Two patients underwent detailed ophthalmologic examination, including optical coherence tomography, full-field electroretinography, and multifocal electroretinography (mfERG; appendix e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000183)).

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

This study was approved by the responsible regional ethical standards committees. Informed consent was obtained from all participants.

RESULTS {#s2}
=======

Data were compiled from 21 members of F1 and 6 members of F2. The pedigrees, individual neurologic phenotype, and *SAMD9L* genotype are shown in [figure 1](#F1){ref-type="fig"} and [table](#T1){ref-type="table"}, and patient descriptions in appendix e-1 and videos 1--3. DNA was obtained from 18 members of F1 and 6 members from F2. All mutation carriers who were examined within this study showed neurologic signs except the 4-year-old mutation carrier, F1: V-2, who had no obvious neurologic signs or symptoms according to her parents. Individual F1: IV-5 declined participation. Thirteen family members were examined who were subsequently shown not to carry *SAMD9L* mutations; these did not have neurologic signs or symptoms.

![Pedigrees of the Swedish and Finnish families with Ataxia-pancytopenia syndrome and *SAMD9L* mutations\
Standard symbols are used. Several members\' sex is disguised (diamond-shaped symbols) and some family members are not included for reasons of confidentiality or lack of consent for this study. Solid symbols indicate neurologic signs or symptoms. (A) Family 1 (Swedish): mut: heterozygote *SAMD9L* c.2956C\>T, p.Arg986Cys mutations in DNA from buccal swabs. Wt: wild-type. Asterisk (\*): 3 individuals also carry the rare variant c.689C\>A p.Thr233Asn, located in *trans* in IV-3 and IV-4. The c.2956C\>T mutation leads to a gain of function of SAMD9L\'s inhibitory functions on cell-cycle regulation, whereas c.689C\>A was hypothesized to ameliorate this effect through a loss of function. (B) Family 2 (Finnish): mut: heterozygote *SAMD9L* c.2672T\>C, p.Ile891Thr mutations. Wt: wild-type in DNA extracted from the peripheral blood.](NG2017005124FF1){#F1}

###### 

Summary of the neurologic phenotype of ATXPC with *SAMD9L* mutations
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F1: III-4 presented at our neurology clinic at age 53 years because of mild balance problems and a positive family history ([figure 1](#F1){ref-type="fig"}). No *SAMD9L* mutation was identified in DNA from the peripheral blood, but nonhematopoietic cells from buccal swabs carried heterozygous *SAMD9L* c.2956C\>T (p.Arg986Cys) mutations.^[@R1]^ His mother and maternal grandmother had similar symptoms that had progressed slowly. None of the other members of this family sought medical attention because of neurologic or ophthalmologic symptoms, but on direct inquiry, all patients examined reported mild balance impairment, for example during sports, and problems with gaze fixation.

F2: II-4 was referred to a pediatric neurologist at the age of 7 years after a single seizure during sleep. He had balance impairment, nystagmus, dysmetria, brisk Achilles tendon reflexes and muscle stiffness in the lower limbs. Symptoms had developed during the last months. His mother, F2: I-2, was investigated at the same time at the age of 32 years by a neurologist for memory problems, nystagmus, lower limb weakness, and balance problems. His brother, F2: II-1, had mild neurologic symptoms. The neurologic phenotype within the family ranged from nearly normal to marked disability. As described previously, a heterozygous *SAMD9L* c.2672T\>C (p.Ile891Thr) mutation was identified in DNA from the peripheral blood from all three affected individuals.^[@R1]^

The hematologic disorders of the family members have been described.^[@R1]^ Transient or permanent cytopenia was detected in 8 of 12 patients. Two children underwent hematopoietic stem cell transplantation (HSCT) because of myelodysplastic syndrome at 2 and 4.5 years. One of these patients (F1:V-1) had no neurologic symptoms prior to HSCT, but 3 months later, ataxic gait and nystagmus were noted. Similar treatment did not lead to neurologic worsening in F2: II-4, in whom follow-up MRI showed decreasing white matter abnormalities ([figure 2B](#F2){ref-type="fig"}, appendix e-1).

![Neuroimaging and multifocal electroretinography (mfERG)\
(A and B) Neuroradiologic findings in affected members of family 1 (A) and family 2 (B). Age at examination is provided in parentheses. pHSCT, examination performed posthematopoietic stem cell transplantation for hematologic malignancy. \*Also carry the rare variant *SAMD9L* c.689C\>A in *trans*. Sagittal MRIs reveal cerebellar atrophy in all individuals examined in adult age. Patient F1: V-1 had cerebellar atrophy at 5 years of age, (A) but patient F2: II-1 did not have clear cerebellar atrophy at 5 years of age (not shown). Later, at the age of 12 years and 9 months F2: II-1 and F2: II-4 at the age of 7 years and 7 months, both had mild cerebellar atrophy (B). Bilateral hyperintense signal changes were visible in the frontoparietal periventricular white matter on T2-FLAIR images to a variable degree in all patients, except the 2 adults with the rare variant *SAMD9L* c.689C\>A (A and B). Frontoparietal white matter changes of F2: II-4 and F2: II-1 decreased during childhood (B). F1: V-1 showed the most prominent white matter changes after hematologic malignancy and 3 months post-HSCT (A), but the white matter changes in F2: II-4, who also had hematologic malignancy and HSCT, decreased (B). For F1: V-1, the follow-up examinations 9 and 21 months post-HSCT showed unchanged widespread white matter abnormalities (not shown). FLAIR images revealed white matter abnormalities in the peritrigonal area in the individuals examined at 5 years and younger (B) that might be a sign of incomplete myelination normal to this age (see appendix e-1). Since there were also peritrigonal white matter signal abnormalities in the adult patient F2: I-2 (B), they might indicate vulnerability of these areas in *SAMD9L*-related ATXPC. CT of patient F1: II-3 showed cerebellar atrophy and diffuse periventricular hypodensities of the cerebral white matter (A). (C) mfERG of 2 patients, compared to normal findings in an adult, shows reduced paracentral function in both patients, to a different degree. N, normal; ↓, significantly reduced function. Fundus photography and optical coherence tomography showed normal results (appendix e-1). ATXPC = ataxia-pancytopenia; FLAIR = fluid-attenuated inversion recovery; ms and MS, milliseconds.](NG2017005124FF2){#F2}

F1: III-4 had noticed difficulties with gaze fixation during several years, and sometimes experienced difficulty reading or tendency to manual clumsiness, for example, when dining. Also, he sometimes found it cumbersome to see in conditions with low ambient light, such as during dawn, dusk, or in foggy weather conditions. Examination by mfERG, which reflects cone function in the posterior pole, demonstrated a reduction of paramacular cone function ([figure 2C](#F2){ref-type="fig"}). In F1: IV-4, there was similar but milder paracentral retinal dysfunction. Other patients from both families reported very similar symptoms.

DISCUSSION {#s3}
==========

The neurologic phenotype of ATXPC with *SAMD9L* mutations is characterized by nystagmus and slowly progressive balance impairment. These signs were found in almost all *SAMD9L* mutation carriers examined in this study ([table](#T1){ref-type="table"}). The neuro-otological findings indicate midline cerebellar dysfunction. Balance impairment was clearly visible on examination,^[@R6]^ but it was mild or very mild in some patients with only difficulty with tandem walking or standing in a tandem position. Additional signs include mild pyramidal signs, strabismus, and decreased vibration sense. Neuroimaging revealed marked cerebellar atrophy in all 8 patients and periventricular white matter changes in 6 of 8 ([figure 2](#F2){ref-type="fig"}). Attention deficit hyperactivity disorder or cognitive problems were noticed in 4 patients, but it remains uncertain if these are related to the disorder.

Ophthalmological symptoms or signs have not previously been described for ATXPC with *SAMD9L* mutations. Adult patients from both families reported reading and focusing difficulties. mfERG showed intact function in the most central area but marked paracentral (cone) dysfunction, which correlates with these visual symptoms. Similar ophthalmologic findings have been reported, for example, in patients with SCA7.^[@R7]^ We suggest that some of the "atactic" signs in the upper extremities noted in patients with *SAMD9L* mutations may in fact be caused by a decrease in visual control of hand movements, rather than cerebellar ataxia.

In our as well as all previously reported families, all carriers of pathogenic *SAMD9L* mutations developed neurologic signs. Expressivity was variable from individuals experiencing marked balance impairment to those who only noticed mild problems with balance or gaze fixation. Careful neurologic examination, however, revealed clearly abnormal signs in all carriers with complete penetrance. The hematologic disorders in members of both families have previously been described in detail.^[@R1]^ In these and the other families, there was pancytopenia with a risk of severe hemorrhages or infections on the one hand, and myelodysplastic syndrome on the other hand, but these hematologic abnormalities were not noticed in all mutation carriers ([table](#T1){ref-type="table"}).

One of SAMD9L\'s roles is that of a tumor suppressor or inhibitor of uncontrolled cell division.^[@R8]^ There is strong evidence that the disease-causing mutations exert a gain-of-function mechanism, resulting in more pronounced inhibition of cell division, which in blood cell lineages causes pancytopenia and genetic pressure to eliminate the mutant copy of the *SAMD9L* gene.^[@R1]^ Also in ataxia-telangiectasia, cerebellar degeneration co-occurs with immunologic deficiencies, lymphopenia, and increased risk of lymphoid malignancies.^[@R9]^ While dysfunction of DNA repair caused by mutations in *ATM* underlies some of the features of ataxia-telangiectasia, the cause of cerebellar degeneration in ataxia-telangiectasia remains difficult to explain. Perhaps similar to SAMD9L, ATM also influences cell-cycle signaling and cellular homeostasis pathways and interacts with another tumor suppressor, p53, in the cell-cycle control system.^[@R10]^ Cerebellar Purkinje cells and retinal cells might be particularly vulnerable to the effect of *SAMD9L* mutations.
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ADHD

:   attention deficit hyperactivity disorder

ATXPC

:   ataxia-pancytopenia

mfERG

:   multifocal electroretinography
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:   hematopoietic stem cell transplantation
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